CAYSTON Powder and solvent for nebuliser solution (2018)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Cayston 75 mg powder and solvent for nebuliser solution.
Qualitative and quantitative composition
Each vial contains aztreonam lysine equivalent to 75 mg aztreonam. After reconstitution the nebuliser solution contains 75 mg aztreonam. For the full list of excipients, see section 6.1.
Pharmaceutical form
Powder and solvent for nebuliser solution. White to off-white powder.
Therapeutic indications
Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older. Consideration should be given ...
Posology and method of administration
Posology Patients should use a bronchodilator before each dose of Cayston. Short acting bronchodilators can be taken between 15 minutes and 4 hours and long acting bronchodilators can be taken between ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Special warnings and precautions for use
Allergic reactions If an allergic reaction to aztreonam does occur, stop administration of the medicinal product and initiate treatment as appropriate. The occurrence of rash may be indicative of an allergic ...
Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed. However, no evidence of any drug interactions with aztreonam were identified from clinical studies in which Cayston was taken concomitantly with bronchodilators, ...
Fertility, pregnancy and lactation
Pregnancy There are no data from the use of aztreonam in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). Systemic ...
Effects on ability to drive and use machines
Cayston has no or negligible influence on the ability to drive or use machines.
Undesirable effects
Summary of the safety profile Assessment of adverse reactions is based on experience in four Phase 3 clinical studies involving CF patients with chronic P. aeruginosa infection and post-marketing spontaneous ...
Overdose
Adverse reactions specifically associated with overdose of Cayston have not been identified. Since the plasma concentration of aztreonam following administration of Cayston (75 mg) is approximately 0.6 ...
Pharmacodynamic properties
Pharmacotherapeutic group: Antibacterials for systemic use, other beta-lactam antibacterials ATC code: J01DF01 Mechanism of action Aztreonam exhibits activity in vitro against gram-negative aerobic pathogens, ...
Pharmacokinetic properties
Absorption Sputum concentrations Individual patients' sputum aztreonam concentrations exhibited considerable variability. For the combined Phase 3 placebo-controlled studies, ten minutes following a single ...
Preclinical safety data
A 104-week rat inhalation toxicology study to assess the carcinogenic potential of ascending doses of aztreonamdemonstrated no drug-related increase in malignant tumours. Genotoxicity (Chromosomal aberration ...
List of excipients
Powder: L-Lysine Solvent: Sodium chloride Water for injections
Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Shelf life
Shelf life Powder vial: 4 years. Solvent: 3 years. After reconstitution, immediate use of Cayston is recommended. If not used immediately, the reconstituted solution must be stored at 2°C-8°C and used ...
Special precautions for storage
Powder vial and solvent ampoule: Store in a refrigerator (2°C-8°C). May be stored outside a refrigerator but below 25°C for up to 28 days. For storage conditions of the reconstitued medicinal product, ...
Nature and contents of container
Powder vial: Type I amber glass vial with siliconised grey rubber stopper and aluminium tear off overseal with or without a blue cap. Solvent: 1 ml low density polyethylene ampoule. Each 28-day pack of ...
Special precautions for disposal and other handling
Reconstitution Cayston should only be reconstituted with the solvent provided. Following reconstitution, Cayston is a clear, colourless to slightly coloured solution. It is recommended that Cayston be ...
Marketing authorization holder
Gilead Sciences Ireland UC, Carrigtohill, County Cork, T45 DP77, Ireland
Marketing authorization number(s)
EU/1/09/543/001 EU/1/09/543/002
Date of first authorization / renewal of the authorization
Date of first authorisation: 21 September 2009 Date of latest renewal: 26 May 2016
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
